Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Biotest

DB:BIO
Snowflake Description

Reasonable growth potential with imperfect balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BIO
DB
€908M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The last earnings update was 9 days ago. More info.


Add to Portfolio Compare Print
  • Biotest has significant price volatility in the past 3 months.
BIO Share Price and Events
7 Day Returns
13.9%
DB:BIO
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-4.6%
DB:BIO
-7.4%
DE Biotechs
-14.2%
DE Market
BIO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Biotest (BIO) 13.9% 23.3% 19.5% -4.6% -18.2% -27%
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • BIO outperformed the Biotechs industry which returned -7.4% over the past year.
  • BIO outperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
BIO
Industry
5yr Volatility vs Market

BIO Value

 Is Biotest undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Biotest to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Biotest.

DB:BIO Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.4%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:BIO
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.05
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.048 (1 + (1- 30%) (45.19%))
1.254
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.25
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.254 * 5.44%)
6.43%

Discounted Cash Flow Calculation for DB:BIO using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Biotest is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:BIO DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 6.43%)
2020 -53.00 Analyst x1 -49.80
2021 -44.00 Analyst x1 -38.84
2022 -64.00 Analyst x1 -53.08
2023 -35.00 Analyst x1 -27.27
2024 36.00 Analyst x1 26.36
2025 51.11 Est @ 41.97% 35.16
2026 66.07 Est @ 29.26% 42.70
2027 79.52 Est @ 20.37% 48.29
2028 90.77 Est @ 14.14% 51.79
2029 99.65 Est @ 9.78% 53.42
Present value of next 10 years cash flows €88.00
DB:BIO DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= €99.65 × (1 + -0.39%) ÷ (6.43% – -0.39%)
€1,454.63
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €1,454.63 ÷ (1 + 6.43%)10
€779.75
DB:BIO Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €88.00 + €779.75
€867.75
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €867.75 / 39.57
€21.93
DB:BIO Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:BIO represents 1.00437x of XTRA:BIO3
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.00437x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 21.93 x 1.00437
€22.02
Value per share (EUR) From above. €22.02
Current discount Discount to share price of €23.00
= -1 x (€23.00 - €22.02) / €22.02
-4.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Biotest is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Biotest's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Biotest's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:BIO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in EUR €-0.12
XTRA:BIO3 Share Price ** XTRA (2020-04-08) in EUR €22.9
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Biotest.

DB:BIO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= XTRA:BIO3 Share Price ÷ EPS (both in EUR)

= 22.9 ÷ -0.12

-192.81x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biotest is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Biotest is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Biotest's expected growth come at a high price?
Raw Data
DB:BIO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -192.81x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
60%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Biotest, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Biotest's assets?
Raw Data
DB:BIO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in EUR €12.05
XTRA:BIO3 Share Price * XTRA (2020-04-08) in EUR €22.9
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:BIO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= XTRA:BIO3 Share Price ÷ Book Value per Share (both in EUR)

= 22.9 ÷ 12.05

1.9x

* Primary Listing of Biotest.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biotest is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Biotest's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Biotest has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

BIO Future Performance

 How is Biotest expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
60%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Biotest expected to grow at an attractive rate?
  • Biotest's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Biotest's earnings growth is expected to exceed the Germany market average.
  • Biotest's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:BIO Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:BIO Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 60%
DB:BIO Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 14.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:BIO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:BIO Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 825 1
2023-12-31 756 1
2022-12-31 630 12 1
2021-12-31 525 -5 1
2020-12-31 457 -25 1
2020-04-08
DB:BIO Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-12-31 419 -34 -5
2019-09-30 406 -20 -9
2019-06-30 395 -6 -3
2019-03-31 390 -26 -6
2018-12-31 400 -50 -13
2018-09-30 405 -16 18
2018-06-30 409 6 6
2018-03-31 400 15 1
2017-12-31 378 34 -16
2017-09-30 257 8 -48
2017-06-30 301 -8 -47
2017-03-31 340 35 -29

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Biotest's earnings are expected to grow significantly at over 20% yearly.
  • Biotest's revenue is expected to grow by 14.4% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:BIO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Biotest Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:BIO Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.29 0.29 0.29 1.00
2021-12-31 -0.12 -0.12 -0.12 1.00
2020-12-31 -0.64 -0.64 -0.64 1.00
2020-04-08
DB:BIO Past Financials Data
Date (Data in EUR Millions) EPS *
2019-12-31 -0.12
2019-09-30 -0.25
2019-06-30 -0.06
2019-03-31 -0.16
2018-12-31 -0.33
2018-09-30 0.45
2018-06-30 0.14
2018-03-31 0.01
2017-12-31 -0.41
2017-09-30 -1.31
2017-06-30 -1.22
2017-03-31 -0.73

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Biotest is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Biotest's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Biotest has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

BIO Past Performance

  How has Biotest performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Biotest's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Biotest does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Biotest's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Biotest's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Biotest's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Biotest Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:BIO Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 419.10 -4.70 82.50 53.40
2019-09-30 405.60 -9.20 81.60 51.70
2019-06-30 394.70 -2.90 82.10 53.30
2019-03-31 389.80 -6.00 82.30 50.60
2018-12-31 400.30 -12.90 84.70 48.50
2018-09-30 404.70 18.00 90.90 49.80
2018-06-30 408.70 5.80 91.40 51.60
2018-03-31 400.40 0.50 99.20 54.40
2017-12-31 378.10 -16.40 100.30 55.40
2017-09-30 257.20 -48.30 95.10 56.20
2017-06-30 300.50 -47.00 92.80 51.60
2017-03-31 340.10 -29.30 89.30 48.70
2016-12-31 408.00 6.00 87.80 48.30
2016-09-30 530.50 128.30 78.10 35.50
2016-06-30 524.50 52.00 87.90 61.70
2016-03-31 525.70 35.90 87.90 72.40
2015-12-31 534.60 27.00 93.40 78.50
2015-09-30 590.00 -88.10 107.40 92.80
2015-06-30 605.60 3.20 108.90 72.90
2015-03-31 602.30 15.60 109.60 68.60
2014-12-31 582.00 19.20 107.80 67.20
2014-09-30 543.20 27.30 105.30 71.50
2014-06-30 521.60 30.50 97.90 68.70
2014-03-31 504.30 30.00 95.00 67.30
2013-12-31 500.80 32.00 92.50 64.60
2013-09-30 482.60 31.50 93.70 57.70
2013-06-30 463.10 28.50 92.40 55.10

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Biotest has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • Biotest used its assets less efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • It is difficult to establish if Biotest improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Biotest's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Biotest has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

BIO Health

 How is Biotest's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Biotest's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Biotest is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Biotest's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Biotest's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Biotest Company Filings, last reported 3 months ago.

DB:BIO Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 476.90 383.70 73.30
2019-09-30 491.70 360.70 99.60
2019-06-30 496.20 336.10 81.70
2019-03-31 493.90 352.70 95.90
2018-12-31 495.20 326.10 77.10
2018-09-30 505.30 353.10 156.40
2018-06-30 499.00 615.50 461.00
2018-03-31 340.10 471.30 171.60
2017-12-31 347.80 402.90 22.90
2017-09-30 331.40 412.40 32.00
2017-06-30 339.50 414.30 64.40
2017-03-31 335.90 350.50 48.90
2016-12-31 360.70 342.60 84.20
2016-09-30 407.00 347.80 130.00
2016-06-30 416.70 349.60 166.20
2016-03-31 410.10 349.20 171.00
2015-12-31 412.30 340.80 154.10
2015-09-30 398.20 347.20 88.30
2015-06-30 484.00 348.40 96.80
2015-03-31 502.90 344.40 125.00
2014-12-31 480.20 331.90 234.10
2014-09-30 486.80 249.10 79.50
2014-06-30 468.10 246.70 89.80
2014-03-31 465.70 246.10 174.20
2013-12-31 460.70 231.50 204.40
2013-09-30 456.30 98.10 70.70
2013-06-30 452.80 102.60 97.30
  • Biotest's level of debt (80.5%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (69.1% vs 80.5% today).
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on Biotest's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess Biotest's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Biotest has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

BIO Dividends

 What is Biotest's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.17%
Current annual income from Biotest dividends. Estimated to be 0.32% next year.
If you bought €2,000 of Biotest shares you are expected to receive €3 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Biotest's pays a lower dividend yield than the bottom 25% of dividend payers in Germany (1.63%).
  • Biotest's dividend is below the markets top 25% of dividend payers in Germany (4.61%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:BIO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:BIO Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.14 1.00
2021-12-31 0.04 1.00
2020-12-31 0.04 1.00
2020-04-08
DB:BIO Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2020-03-30 0.040 0.195
2019-03-28 0.040 0.187
2018-03-23 0.040 0.168
2017-03-30 0.070 0.321
2016-03-23 0.040 0.278
2015-05-07 0.220 1.304
2014-05-07 0.210 0.705
2013-05-08 0.187 0.839
2012-03-22 0.167 1.126
2012-01-16 0.167 1.279
2011-03-17 0.147 1.075

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biotest is not paying a notable dividend for Germany, therefore no need to check if the payments are stable.
  • Biotest is not paying a notable dividend for Germany, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Biotest's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Biotest's dividends as it is not paying a notable one for Germany.
Future Payout to shareholders
  • No need to calculate the sustainability of Biotest's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Biotest's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Biotest afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Biotest has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

BIO Management

 What is the CEO of Biotest's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Michael Ramroth
COMPENSATION €1,012,000
AGE 58
TENURE AS CEO 0.9 years
CEO Bio

Dr. Michael Ramroth serves as Chairman of the Management Board and CEO at Biotest Aktiengesellschaft since May 01, 2019. Dr. Ramroth serves as Chief Financial Officer at Biotest Aktiengesellschaft. He served as Head of Finances and Central Services at Biotest Aktiengesellschaft until 2019. Dr. Ramroth has been a Member of the Board of Management at Biotest AG since February 1, 2004 and responsible for Finances and Central Services. Dr. rer. pol. Ramroth serves as the Chief Financial Officer and Head of Finances and Central Services of Biotest AG. From 1990 to 1997, he served as Head of the Business Development Department at Metallgesellschaft AG. He served as Chief Financial Officer of MG Technologies AG since 1999 until 2003. He served as a Member of the Executive Board (deputy), mg technologies ag, Frankfurt/Main, Parent Company of GEA AG until December 31, 2002. Dr. rer. pol. Ramroth also served as Chairman of the Supervisory Board of Frankfurter Assekuranz-Kontor GmbH and mg vermögensverwaltungs-ag. He serves as a Member of Senior Advisor Board of Clearwater International GmbH. He has been a Director of Biotest UK Ltd. since 2004. He served as a member of the Supervisory Board of Lurgi AG, until December 31, 2002 and GEA AG until January 30, 2003. From 1997 to 1999, he served as Director of CeramTec AG. He served as a Director at MG Technologies AG. Dr. rer. pol. Ramroth is a lawyer and obtained his doctorate in political economy.

CEO Compensation
  • Michael's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Michael's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Biotest management team in years:

4.7
Average Tenure
  • The tenure for the Biotest management team is about average.
Management Team

Michael Ramroth

TITLE
Chairman of the Management Board
COMPENSATION
€1M
AGE
58
TENURE
0.9 yrs

Georg Floß

TITLE
COO & Member of the Board of Management
COMPENSATION
€888K
TENURE
7.3 yrs

Monika Buttkereit

TITLE
Head of Investor Relations

Christina Erb

TITLE
Head of Corporate HR
TENURE
4.7 yrs

Katrin Bernöster

TITLE
Head of the Project Management Organisation

Peter Seith

TITLE
Head of Quality Operations

Jörg Schüttrumpf

TITLE
Head of Research & Development

Wolfgang Möller

TITLE
Head of Development - Plasma Protein

Hermann Keuper

TITLE
Senior Vice President of Manufacturing
Board of Directors Tenure

Average tenure of the Biotest board of directors in years:

5.6
Average Tenure
  • The tenure for the Biotest board of directors is about average.
Board of Directors

Rolf Hoffmann

TITLE
Chairman of the Supervisory Board
AGE
60
TENURE
2.7 yrs

Tan Yang

TITLE
Deputy Chairman of Supervisory Board
COMPENSATION
€50K
TENURE
2.1 yrs

Cathrin Schleussner

TITLE
Member of the Supervisory Board
COMPENSATION
€37K
TENURE
8.8 yrs

Simone Fischer

TITLE
Member of Supervisory Board
TENURE
0.2 yrs

Kerstin Birkhahn

TITLE
Member of Supervisory Board
COMPENSATION
€34K
TENURE
10 yrs

Jurgen Heilmann

TITLE
Member of Supervisory Board
COMPENSATION
€34K
TENURE
8.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Biotest's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Biotest has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

BIO News

Simply Wall St News

BIO Company Info

Description

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for the treatment of haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; and Vihuma for treating haemophilia A acute therapy and prophylaxis. The company’s products also comprise Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect for prophylaxis of hepatitis B re-infection; Intratect for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; IgG Next Genration for primary immune deficiency and immunothrombocytopenia; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin for the treatment of blood volume depletion; Biseko to treat volume and serum protein depletion; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital and acquired fibrinogen deficiency; Trimodulin for the community-acquired pneumonia; and Pentaglobin to treat bacterial infections. The company’s products under development include BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) to treat cytomegalovirus infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Tiancheng International Investment Limited.

Details
Name: Biotest Aktiengesellschaft
BIO
Exchange: DB
Founded: 1946
€908,164,823
39,571,452
Website: http://www.biotest.com
Address: Biotest Aktiengesellschaft
Landsteinerstrasse 5,
Dreieich,
63303,
Germany
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
XTRA BIO3 Preference Shares XETRA Trading Platform DE EUR 06. Jan 1992
OTCPK BIES.F Preference Shares Pink Sheets LLC US USD 06. Jan 1992
DB BIO3 Preference Shares Deutsche Boerse AG DE EUR 06. Jan 1992
LSE 0N70 Preference Shares London Stock Exchange GB EUR 06. Jan 1992
SWX BIO3 Preference Shares SIX Swiss Exchange CH CHF 06. Jan 1992
WBAG BIO3 Preference Shares Wiener Boerse AG AT EUR 06. Jan 1992
BATS-CHIXE BIO3D Preference Shares BATS 'Chi-X Europe' GB EUR 06. Jan 1992
XTRA BIO Ordinary Shares XETRA Trading Platform DE EUR 03. Jun 1996
DB BIO Ordinary Shares Deutsche Boerse AG DE EUR 03. Jun 1996
LSE 0N6Z Ordinary Shares London Stock Exchange GB EUR 03. Jun 1996
BATS-CHIXE BIOD Ordinary Shares BATS 'Chi-X Europe' GB EUR 03. Jun 1996
Number of employees
Current staff
Staff numbers
1,837
Biotest employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 20:52
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/04/03
Last earnings filing: 2020/03/30
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.